WO2003044185A3 - Purified polypeptides involved in general metabolism - Google Patents

Purified polypeptides involved in general metabolism Download PDF

Info

Publication number
WO2003044185A3
WO2003044185A3 PCT/CA2002/001768 CA0201768W WO03044185A3 WO 2003044185 A3 WO2003044185 A3 WO 2003044185A3 CA 0201768 W CA0201768 W CA 0201768W WO 03044185 A3 WO03044185 A3 WO 03044185A3
Authority
WO
WIPO (PCT)
Prior art keywords
purified polypeptides
polypeptides involved
general metabolism
metabolism
general
Prior art date
Application number
PCT/CA2002/001768
Other languages
French (fr)
Other versions
WO2003044185A2 (en
Inventor
Aled Edwards
Akil Dharamsi
Masoud Vedadi
Muhammad Zahoor Alam
Donald Awrey
Bryan Beattie
Veronica Canadien
Megan Domagala
Simon Houston
Kamran Mansoury
Sasha Necakov
Kathleen Nethery
Ivy Ng
Benjamin Pinder
Bay Sheldrick
Francois Vallee
Olga Wrezel
Original Assignee
Affinium Pharm Inc
Aled Edwards
Akil Dharamsi
Masoud Vedadi
Muhammad Zahoor Alam
Donald Awrey
Bryan Beattie
Veronica Canadien
Megan Domagala
Simon Houston
Kamran Mansoury
Sasha Necakov
Kathleen Nethery
Ivy Ng
Benjamin Pinder
Bay Sheldrick
Francois Vallee
Olga Wrezel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affinium Pharm Inc, Aled Edwards, Akil Dharamsi, Masoud Vedadi, Muhammad Zahoor Alam, Donald Awrey, Bryan Beattie, Veronica Canadien, Megan Domagala, Simon Houston, Kamran Mansoury, Sasha Necakov, Kathleen Nethery, Ivy Ng, Benjamin Pinder, Bay Sheldrick, Francois Vallee, Olga Wrezel filed Critical Affinium Pharm Inc
Priority to AU2002364783A priority Critical patent/AU2002364783A1/en
Publication of WO2003044185A2 publication Critical patent/WO2003044185A2/en
Priority to US10/806,062 priority patent/US20050214773A1/en
Publication of WO2003044185A3 publication Critical patent/WO2003044185A3/en
Priority to US10/922,802 priority patent/US20050187718A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004Oxidoreductases (1.)
    • C12N9/0006Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245Escherichia (G)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/1085Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/78Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2299/00Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to polypeptide targets for pathogenic bacteria. The invention also provides biochemical and biophysical characteristics of those polypeptides.
PCT/CA2002/001768 2001-09-21 2002-11-21 Purified polypeptides involved in general metabolism WO2003044185A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2002364783A AU2002364783A1 (en) 2001-11-21 2002-11-21 Purified polypeptides involved in general metabolism
US10/806,062 US20050214773A1 (en) 2001-09-21 2004-03-22 Novel purified polypeptides from bacteria
US10/922,802 US20050187718A1 (en) 2001-09-21 2004-08-20 Novel purified polypeptides from Streptococcus pneumoniae

Applications Claiming Priority (22)

Application Number Priority Date Filing Date Title
US33216001P 2001-11-21 2001-11-21
US60/332,160 2001-11-21
US33366501P 2001-11-27 2001-11-27
US33366101P 2001-11-27 2001-11-27
US60/333,661 2001-11-27
US60/333,665 2001-11-27
US34177001P 2001-12-18 2001-12-18
US60/341,770 2001-12-18
US34200301P 2001-12-19 2001-12-19
US34195401P 2001-12-19 2001-12-19
US60/342,003 2001-12-19
US60/341,954 2001-12-19
US34254201P 2001-12-20 2001-12-20
US60/342,542 2001-12-20
US34425201P 2001-12-21 2001-12-21
US60/344,252 2001-12-21
US34360601P 2001-12-28 2001-12-28
US34357001P 2001-12-28 2001-12-28
US34367901P 2001-12-28 2001-12-28
US60/343,606 2001-12-28
US60/343,570 2001-12-28
US60/343,679 2001-12-28

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10/806,062 Continuation-In-Part US20050214773A1 (en) 2001-09-21 2004-03-22 Novel purified polypeptides from bacteria
US10/922,802 Continuation-In-Part US20050187718A1 (en) 2001-09-21 2004-08-20 Novel purified polypeptides from Streptococcus pneumoniae

Publications (2)

Publication Number Publication Date
WO2003044185A2 WO2003044185A2 (en) 2003-05-30
WO2003044185A3 true WO2003044185A3 (en) 2004-08-05

Family

ID=27582776

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2002/001768 WO2003044185A2 (en) 2001-09-21 2002-11-21 Purified polypeptides involved in general metabolism

Country Status (2)

Country Link
AU (1) AU2002364783A1 (en)
WO (1) WO2003044185A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2526651T3 (en) 2008-07-03 2015-01-14 Monsanto Technology Llc Combinations of derivatized saccharide surfactants and etheramine oxide surfactants as herbicide adjuvants
JP2013525271A (en) 2010-03-12 2013-06-20 チルドレンズ メディカル センター コーポレーション Immunogen and screening method thereof
WO2014124228A1 (en) 2013-02-07 2014-08-14 Children's Medical Center Corporation Protein antigens that provide protection against pneumococcal colonization and/or disease
WO2020056202A1 (en) 2018-09-12 2020-03-19 Affinivax, Inc. Multivalent pneumococcal vaccines
AU2022342080A1 (en) 2021-09-09 2024-03-28 Affinivax, Inc. Multivalent pneumococcal vaccines

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001021769A2 (en) * 1999-09-23 2001-03-29 Mcgill University THREE-DIMENSIONAL STRUCTURE AND CRYSTAL OF A CLASS I α1,2-MANNOSIDASE, AND METHODS OF USE THEREOF
US6228588B1 (en) * 1995-09-15 2001-05-08 Microcide Pharmaceuticals, Inc. Methods of screening for compounds active on Staphylococcus aureus target genes
WO2001062688A2 (en) * 2000-02-25 2001-08-30 Wyeth Methods of structure-based drug design using ms/nmr
WO2001073436A1 (en) * 2000-03-28 2001-10-04 Wyeth SOLUTION AND CRYSTAL STRUCTURES OF ZipA AND ZipA COMPLEX AND USES THEREOF
WO2001079457A2 (en) * 2000-04-13 2001-10-25 University Health Network Crystal structure for rmlc and uses thereof
EP1158000A1 (en) * 2000-05-23 2001-11-28 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Crystal structure data of cystalysin and use thereof for the design and preparation of inhibitor molecules

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6228588B1 (en) * 1995-09-15 2001-05-08 Microcide Pharmaceuticals, Inc. Methods of screening for compounds active on Staphylococcus aureus target genes
WO2001021769A2 (en) * 1999-09-23 2001-03-29 Mcgill University THREE-DIMENSIONAL STRUCTURE AND CRYSTAL OF A CLASS I α1,2-MANNOSIDASE, AND METHODS OF USE THEREOF
WO2001062688A2 (en) * 2000-02-25 2001-08-30 Wyeth Methods of structure-based drug design using ms/nmr
WO2001073436A1 (en) * 2000-03-28 2001-10-04 Wyeth SOLUTION AND CRYSTAL STRUCTURES OF ZipA AND ZipA COMPLEX AND USES THEREOF
WO2001079457A2 (en) * 2000-04-13 2001-10-25 University Health Network Crystal structure for rmlc and uses thereof
EP1158000A1 (en) * 2000-05-23 2001-11-28 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Crystal structure data of cystalysin and use thereof for the design and preparation of inhibitor molecules

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] XP002268016, retrieved from EBI accession no. EMBL Database accession no. AR149328 *
OTTING GOTTFRIED: "Experimental NMR techniques for studies of protein-ligand interactions", CURRENT OPINION IN STRUCTURAL BIOLOGY, vol. 3, no. 5, 1993, pages 760 - 768, XP009024400, ISSN: 0959-440X *
WHITTLE P J ET AL: "PROTEIN STRUCTURE-BASED DRUG DESIGN", ANNUAL REVIEW OF BIOPHYSICS AND BIOMOLECULAR STRUCTURE, ANNUAL REVIEWS INC., PALO ALTO, CA, US, vol. 23, 1994, pages 349 - 375, XP001008225, ISSN: 1056-8700 *

Also Published As

Publication number Publication date
AU2002364783A1 (en) 2003-06-10
WO2003044185A2 (en) 2003-05-30
AU2002364783A8 (en) 2003-06-10

Similar Documents

Publication Publication Date Title
WO2004041854A3 (en) Essential novel bacterial polypeptides
WO2003087353A3 (en) Purified polypeptides involved in membrane biogenesis
WO2003044185A3 (en) Purified polypeptides involved in general metabolism
AU3749499A (en) Novel molecules of the bgckr-related protein family and uses thereof
WO2003025006A3 (en) Purified polypeptides involved in co-factor metabolism
WO2003083099A3 (en) Purified polypeptides involved in protein synthesis and modification
WO2003084986A3 (en) Novel purified polypeptides involved in cellular metabolism
WO2004044189A3 (en) Novel purified polypeptides involved in metabolism
WO2003102190A3 (en) Bacterial polypeptides involved in viability
AU3965799A (en) Novel molecules of the t125-related protein family and uses thereof
WO2003025004A3 (en) Purified bacterial polypeptides involved in nucleic acid processing
WO2003027139A3 (en) Novel purified polypeptides involved in membrane biosynthesis
AU2002362414A1 (en) Novel molecules of the hkid-1-related protein family and uses thereof
WO2003045986A3 (en) Purified polypeptides involved in general metabolism as possible drug targets
WO2003025008A3 (en) Bacterial polypeptides involved in protein processing
WO2003087145A3 (en) Purified polypeptides involved in quorum sensing
WO2003025007A3 (en) Purified polypeptides involved in membrane biosynthesis
WO2003045985A3 (en) Purified polypeptides involved in carbohydrate and coenzyme metabolism
WO2003025005A3 (en) Purified bacterial polypeptides involved in protein processing
WO2003035858A3 (en) Bacterial polypeptides involved in nucleic acid processing
WO2003087354A3 (en) Novel purified polypeptides involved in nucleotide transport and metabolism
WO2003085103A3 (en) Purified polypeptides involved in nucleotide hydrolysis
WO2003084987A3 (en) Polypeptides from bacteria and uses thereof
WO2004058809A3 (en) Novel essential bacterial polypeptides
WO2003097789A3 (en) Farnesyl diphosphate synthase from pseudomonas aeruginosa

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP